Target intelligence / Profile preview

Bile acids (BA)

Target
BA
Molecular classification
Other, Steroid, Lipid, Metabolic intermediate
01

Overview

Bile acids are steroid-based molecules synthesized from cholesterol in the liver and released into the small intestine to facilitate the digestion and absorption of dietary lipids and fat-soluble vitamins (Hofmann, 1999). They function as essential detergents and signaling molecules, activating key metabolic receptors like the Farnesoid X receptor (FXR) and TGR5 to maintain systemic lipid and glucose homeostasis (Chiang, 2009). In clinical practice, bile acids in the intestinal lumen serve as a therapeutic target for bile acid sequestrants, which are used to treat hypercholesterolemia and bile acid diarrhea (StatPearls, 2023). By binding bile acids and preventing their reabsorption, these drugs promote the fecal excretion of bile salts, prompting the liver to upregulate the conversion of cholesterol into new bile acids. This mechanism effectively reduces circulating LDL cholesterol levels and alleviates symptoms associated with bile acid malabsorption. However, targeting luminal bile acids can lead to gastrointestinal side effects and may interfere with the absorption of other medications and nutrients.

Other names
Bile saltsSteroid acidsPrimary bile acidsSecondary bile acidsCholic acid derivatives
02

Mechanism of action

Bile acid sequestrants are large, positively charged polymers that bind to negatively charged bile acids in the intestinal lumen through ionic bonding, forming an insoluble complex that is excreted in the feces, thereby preventing reabsorption and interrupting the enterohepatic circulation.

03

Biological functions

Lipid digestionCholesterol homeostasisSignal transductionMetabolic regulationEmulsification of dietary fats
04

Disease associations

HypercholesterolemiaBile acid malabsorptionPrimary biliary cholangitisType 2 diabetesPruritusNonalcoholic steatohepatitis (NASH)
05

Safety considerations

Gastrointestinal distress (constipation, bloating, flatulence)Malabsorption of fat-soluble vitamins (A, D, E, K)Drug-drug interactions due to non-specific binding of co-administered medicationsHypertriglyceridemia
06

Interacting drugs

Cholestyramine

2 more in the full profile.

07

Biomarkers

Low-density lipoprotein cholesterol (LDL-C)7α-hydroxy-4-cholesten-3-one (C4)Fibroblast growth factor 19 (FGF19)Fecal bile acid levels

Beyond the preview

Go deeper on Bile acids (BA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bile acids (BA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call